Hualing Pharmaceutical-B (02552) rose more than 6%. As of press release, it rose 6.19% to HK$2.4, with a turnover of HK$6.734,900.
The Zhitong Finance App learned that Hualing Pharmaceutical-B (02552) rose by more than 6%. As of press release, it had risen 6.19% to HK$2.4, with a turnover of HK$6.734,900.
According to the news, Hualing Pharmaceutical previously announced that it has submitted its experimental new drug (IND) application for a second-generation glucokinase activator (second-generation GKA) to the US FDA to begin phase 1 clinical trials. In addition, the company independently developed the world's first novel drug for diabetes, glucose kinase activator (GKA), doglietine (trade name: Huatangning) was also successfully included in the national medical insurance drug catalogue. The medical insurance payment standard is 5.39 yuan per tablet.
Pacific Securities believes that Huatangning's clinical value and market monopoly are important factors in the high pricing of medical insurance. Furthermore, Bayer's academic promotion efforts are expected to increase dramatically, and Huatangning's sales volume is worth looking forward to. The bank also pointed out that considering that Huatangning has completed 3 clinical trials of drug interaction with metformin, sitagliptin, and engglitine in the US in 2015-2020, the bank expects the safety data for the upgraded version of Huatangning in the US to meet expectations.